Member Info for Largo

Https://gov.krd/dmi-en/activities/news-and-press-releases/2023/may/krg-reaches-agreement-with-baghdad-on-oil-exports/

The Kurdistan Regional Government has reached an agreement with the Iraqi federal government on measures to allow the resumption of oil exports through Turkey.

The Kurdistan Region’s Ministry of Natural Resources announced in a statement that on 10 May Iraq's State Oil Marketing Organization (SOMO) officially requested Turkish authorities to allow the Kurdistan Region’s oil exports via the country's Ceyhan port.

Both The Kurdistan Region’s Ministry of Natural Resources and Iraq’s Ministry of Oil are reportedly waiting for Turkey’s response before resuming oil exports.

11 May 2023

The timing of the Citadel 0.51% short in GKP doesn't look so good :!

Or is this another false hope.!

Shafaq News/ Iraq's state oil marketer, SOMO, has formally invited Turkey to resume oil exports from Kurdistan, the region's ministry of natural resources said in a press release on Thursday.

This announcement followed an agreement between the Kurdistan Regional Government (KRG) and the Federal Government of Iraq regarding the region's oil portfolio.

"After reaching an accord between the Kurdistan Regional Government and the Iraqi Federal Government pertaining to the region's oil dossier, the requisite procedures to recommence oil exports have been finalized," the press release said.

"on May 10th, SOMO officially solicited the Turkish side to initiate oil exports via the Kirkuk-Ceyhan pipeline," it added.

The statement underscored that both, the regional ministry of natural resources and the federal ministry of oil are awaiting Turkey's response to SOMO's request.

Crude exports from the semiautonomous Kurdistan region have been suspended since late March, caught up in a dispute between Turkey and Iraq over exports by the Kurdistan Regional Government (KRG). With the pipeline to the Turkish port of Ceyhan, the only viable outlet for the region's crude, storage quickly filled and fields were shut in. Iraq's state-owned marketing firm said this week that the country's crude production fell by 360,000 b/d because of the northern impasse.

The shutdown appeared to affect regional production in the first quarter, even though it began only a week before the end of the period.

Baghdad and the Kurdistan Regional Government (KRG) signed a temporary agreement on April 4 to restart oil exports to Turkey, but the implementation was delayed as the two needed to iron out some aspects of the deal.

Related to block listing of a total of 6,250,000 common shares yesterday IMHO.

And Aberdeen have increased there holding by 56.41%

6.09% abrdn plc 13,152,902 $18.5m + 56.41%

As well as Acadian +20.56%

4.18%

Acadian Asset Management LLC 9,031,297 $12.7m +20.56%

Since April.

"80% buying today.
Some of the majors making significant headcount, they know where to look, ASCO and more news flow coming up.
Would not be surprised to see further size prints post hours."

"Size buyer back in town"

"145-50 I’m NY size"

Hurstbot at his best!

gibberish nonsense..I

Outlook.
The Board believe that the significant near-term value driver for the Group is the clinical data from the Phase I study of AVA6000. The pre|CISIONTM FAPa-activation approach has the potential to reduce the systemic toxicities associated with many chemotherapies and as such has the potential to create safer and more effective oncology treatments that are affordable for all.
The outlook for AVA6000 and the pre|CISIONTM platform as a whole looks very promising, based on the safety, pharmacokinetic and tumour biopsy data obtained to date. The next significant value driver for AVA6000 will be the initial efficacy data from the Phase 1b dose expansion phase in patients with soft tissue sarcoma.
Avacta Diagnostics continues to actively pursue other M&A opportunities to build a fully integrated and differentiated European diagnostics business. These focus on expanding our routes to market for both professional and consumer testing products, while adding further IVD products suitable for these markets to our portfolio.
I believe that the progress made during 2022 puts the Group in a very strong position and we are confident and excited about the future.

Sounds good to me..1

It closed at 138.20 down 0.8%
Not ....10 Pence.

Forces are at play here and I told you that weeks ago.
MM's are selling into any rise to hold the SP.
IMHO...there is are very large buyer.!
BFTFDIK...only been doing this for 40 years.
GLLTH.

Hurstbot and the NewYork Buyers...!

LOL...Föcking hilarious.

rogthegamer.I think there will be a lot of discussions now between all the Kurdistan oil companies and the authorities.
Price,volumes,back pay,Psc's for instance.
It's a hole new ballgame.
And a little more than "The taps are back on" imho.

Intervention Model Description: This Phase I study will follow a standard 3+3 design in Part 1a to determine the maximum tolerated dose (MTD) and/or recommended dose of AVA6000, given as an intravenous infusion, to be used in Part 1b in the dose-expansion phase in up to 3 tumour types.

Experimental: AVA6000 Phase 1a
Patients in Phase Ia will receive escalating doses of AVA6000 following a 3+3 design, commencing with a starting dose of 80mg/m2, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.

Experimental: AVA6000 Phase 1b
Patients in Phase Ib will receive the RP2D dose of AVA6000, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first. One to three tumour types will be selected based on the assessment of Phase 1a data.

Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : June 30, 2023

https://clinicaltrials.gov/ct2/show/NCT04969835

Is he peeing on his violin...!

Nope!!!! Wait and see , Which Company will be announcing they are pushing the oil down the pipeline first ???

GL with your holding long term holders will come through!

You see isn't that better.!

opulentia.. are you spending false news again?

I have got so say you are one helluva rampa..!

Sorry for the typo's.

Roxi..May-be the LTH are so dumb after all.

It's paid for some nice little holidays for me too.

GL.

Opulentia.
I remember you form the old days.
You've got more shares than Todd Kozell.LOL

For God's sake..!

RNS Number : 3893V
Avacta Group PLC
05 April 2023




5 April 2023

Avacta Group plc

("Avacta" and, together with its subsidiary undertakings, the "Group")

First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial (ALS-6000-101) of AVA6000. This follows the approval of an amended clinical trial protocol by the Medical and Healthcare Products Regulatory Agency (MHRA) to allow for higher levels of dosing.

Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has recommended that the phase Ia dose escalation clinical trial continues to a fifth dose cohort at 250mg/m2, following the favourable safety profile of AVA6000 generated in the study to date. Escalation to this level of dosing falls outside of the original clinical trial protocol, and therefore the protocol required amendment and approval by the MHRA, which has now been completed. This continued dose escalation is aimed at identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

"We are very much encouraged by the positive safety and tolerability data emerging from the dose escalation phase 1a study of AVA6000. Following the recommendation from the SDMC, and approval by the MHRA, we are pleased to commence dosing in the fifth patient cohort of this trial.

The recent confirmation of release of active chemotherapy in the tumour tissue and the safety data being generated in the ALS-6000-101 study are providing detailed insights into the pre|CISION™ platform which add significant value to the technology and confirm the tumour targeting potential of the pre|CISION™ platform."

This announcement has been approved for release by Alastair Smith, Chief Executive Officer of Avacta Group plc.


-Ends-

Correct!